---
figid: PMC5961736__nihms964503f4
figtitle: PD-1/PD-Ls signaling pathway that acts as effective therapeutic targets
  in lymphoma
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC5961736
filename: nihms964503f4.jpg
figlink: /pmc/articles/PMC5961736/figure/F4/
number: F4
caption: Overview of PD-1/PD-Ls signaling pathway that acts as effective therapeutic
  targets in lymphoma. Upon binding to its ligands PD-Ls, PD-1 delivers co-inhibitory
  signals, negatively regulating T-cell function to maintain immune balance. In the
  cases of tumor, overexpressed PD-Ls activate PD-1 signaling, leading to exhaustion
  of effector T cell after interaction of PD-1 and PD-Ls. Targeting PD-1 and/or PD-L1
  are the current focus of immunotherapy and clinical management in several solid
  tumor and hematologic malignancies. APC, antigen presenting cell; PD-1, programmed
  death-1; PD-L, programmed death-ligand; MHCII, major histocompatibility complex,
  class II; TCR, T-cell receptor; SHP, Src homology region 2 domain-containing phosphatase;
  ZAP70, zeta chain of T cell receptor associated protein kinase 70; PI3K, phosphoinositide-3-kinase;
  AKT, v-akt murine thymoma viral oncogene homolog1; ERK, extracellular signal-regulated
  kinase; FOXO-1, forkhead box 1; mTOR, mechanistic target of Rapamycin; NFAT, nuclear
  factor of activated T cells; NF-kB, nuclear factor-kappa B.
papertitle: Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers
  in Lymphoid Malignancies.
reftext: Ruifang Sun, et al. Crit Rev Oncog. ;22(5-6):527-557.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9603884
figid_alias: PMC5961736__F4
figtype: Figure
redirect_from: /figures/PMC5961736__F4
ndex: 4d7db003-dede-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5961736__nihms964503f4.html
  '@type': Dataset
  description: Overview of PD-1/PD-Ls signaling pathway that acts as effective therapeutic
    targets in lymphoma. Upon binding to its ligands PD-Ls, PD-1 delivers co-inhibitory
    signals, negatively regulating T-cell function to maintain immune balance. In
    the cases of tumor, overexpressed PD-Ls activate PD-1 signaling, leading to exhaustion
    of effector T cell after interaction of PD-1 and PD-Ls. Targeting PD-1 and/or
    PD-L1 are the current focus of immunotherapy and clinical management in several
    solid tumor and hematologic malignancies. APC, antigen presenting cell; PD-1,
    programmed death-1; PD-L, programmed death-ligand; MHCII, major histocompatibility
    complex, class II; TCR, T-cell receptor; SHP, Src homology region 2 domain-containing
    phosphatase; ZAP70, zeta chain of T cell receptor associated protein kinase 70;
    PI3K, phosphoinositide-3-kinase; AKT, v-akt murine thymoma viral oncogene homolog1;
    ERK, extracellular signal-regulated kinase; FOXO-1, forkhead box 1; mTOR, mechanistic
    target of Rapamycin; NFAT, nuclear factor of activated T cells; NF-kB, nuclear
    factor-kappa B.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - APC
  - PROC
  - PDCD1LG2
  - CD274
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - PTPN11
  - CD247
  - CD3D
  - CD3E
  - CD3G
  - ZAP70
  - KRAS
  - HRAS
  - NRAS
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - AKT1
  - AKT2
  - AKT3
  - MAPK3
  - MAPK1
  - MTOR
  - NFKB1
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - RBFOX1
  - Apc
  - Apc2
  - Axn
  - Fs(3)Apc
  - Tcr
  - csw
  - ras
  - Ras64B
  - Ras85D
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Akt
  - rl
  - Mtor
  - Tor
  - Dif
  - dl
  - Rel
  - NFAT
  - CycE
  - cyc
  - foxo
  - Cancer
---
